Applied Chemistry Today

Applied Chemistry Today

Investigation of the Cytotoxic Potencies of substituted dipyrrolo[1,2-a:2',1'-c]pyrazines and substituted pyrrolo[2'',1'':3',4']pyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-8(9H)-ones

Document Type : Original Article

Authors
Azam Barghi Lish 1
Eskandar Kolvari 1
Alireza Foroumadi 2
Nadiya Koukabi 1
1 Faculty of Chemistry, Semnan University, Semnan, Iran
2 Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
10.22075/chem.2024.34180.2272
Abstract
Cancer is the world's second leading cause of death after cardiovascular diseases. The data reported by the World Health Organization (WHO) about this disease indicates a troubling increase in both prevalence and mortality over the past decade. Consequently, significant efforts have been directed toward the discovery and development of a new and potent anticancer agents. In an attempt to find and develop further new compounds possessing cytotoxic potencies, the efficient, simple, and multi-step synthetic routes were employed to afford various substituted dihydrodipyrrolo[1,2-a:2',1'-c]pyrazine-2,3-dicarboxylates 8a-8s, which were subsequently subjected to cyclization in the presence of hydrazine hydrate to produce tetrahydropyrrolo[2'',1'':3',4']pyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-8(9H)-ones 10a-10q. Afterwards, their cytotoxicity were examined against five human cancerous cell lines, including MCF7, HeLa, SW480, HepG2, and A549 by using the MTT colorimetric assay. Considering the results, further evaluations were conducted on the compound 8l, which exhibited the induction of apoptosis and G0 cell cycle arrest in MCF7 and A549 cells.
Keywords
: pyrrolo[1
2-a]pyrazine
5
6-dihydropyrrolo[1
2-a:2'
1'-c]pyrazine
cancer
N-aminoethylpyrrole
aryl glyoxal
dimethyl acetylenedicarboxylate
Subjects
[1] Web. https://www.who.int/news-room/fact-sheets/detail/cancer.
[2] Staff, N. P., Grisold, A., Grisold, W., & Windebank, A. J. (2017). Chemotherapy-induced peripheral neuropathy: A current review. Annals of neurology, 81(6), 772–781.
[3] Chen, H. H. W., & Kuo, M. T. (2017). Improving radiotherapy in cancer treatment: Promises and challenges. Oncotarget, 8(37), 62742–62758.
[4] Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022). Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. Journal of hematology & oncology, 15(1), 143.
[5] Kannaiyan, R., & Mahadevan, D. (2018). A comprehensive review of protein kinase inhibitors for cancer therapy. Expert review of anticancer therapy, 18(12), 1249–1270.
[6] Arora, A., & Scholar, E. M. (2005). Role of tyrosine kinase inhibitors in cancer therapy. The Journal of pharmacology and experimental therapeutics, 315(3), 971–979.
[7] Peerzada, M. N., Dar, M. S., & Verma, S. (2023). Development of tubulin polymerization inhibitors as anticancer agents. Expert opinion on therapeutic patents, 33(11), 797–820.
[8] Hawash M. (2022). Recent Advances of Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer Therapy. Biomolecules, 12(12), 1843.
[9] Yakkala, P. A., Penumallu, N. R., Shafi, S., & Kamal, A. (2023). Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents. Pharmaceuticals (Basel, Switzerland), 16(10), 1456.
[10] Nitiss J. L. (2009). Targeting DNA topoisomerase II in cancer chemotherapy. Nature reviews. Cancer, 9(5), 338–350.
[11] Pérez-Salvia, M., & Esteller, M. (2017). Bromodomain inhibitors and cancer therapy: From structures to applications. Epigenetics, 12(5), 323–339.
[12] To, K. K. W., Xing, E., Larue, R. C., & Li, P. K. (2023). BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications. Molecules (Basel, Switzerland), 28(7), 3043.
[13] Wang, Z. Q., Zhang, Z. C., Wu, Y. Y., Pi, Y. N., Lou, S. H., Liu, T. B., Lou, G., & Yang, C. (2023). Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy. Signal transduction and targeted therapy, 8(1), 420.
[14] Giammona, A., Crivaro, E., & Stecca, B. (2023). Emerging Roles of Hedgehog Signaling in Cancer Immunity. International journal of molecular sciences, 24(2), 1321.
[15] Cortes, J. E., Gutzmer, R., Kieran, M. W., & Solomon, J. A. (2019). Hedgehog signaling inhibitors in solid and hematological cancers. Cancer treatment reviews, 76, 41–50. 
[16] Neckers, L. (2007). Heat shock protein 90: the cancer chaperone. Heat Shock Proteins in Cancer: 231-252.
[17] Zhang, J., Li, H., Liu, Y., Zhao, K., Wei, S., Sugarman, E. T., Liu, L., & Zhang, G. (2022). Targeting HSP90 as a Novel Therapy for Cancer: Mechanistic Insights and Translational Relevance. Cells, 11(18), 2778.
[18] Liang, J., Tian, C., Liu, L., Zeng, X., & Zhang, Y. (2024). Targeting CENP-E augments immunotherapy in non-small cell lung cancer via stabilizing PD-L1. International immunopharmacology, 126, 111294.
[19] El-Arabey, A. A., Salama, S. A., & Abd-Allah, A. R. (2018). CENP-E as a target for cancer therapy: Where are we now?. Life sciences, 208, 192–200.
[20] Tang, H., Wang, L., Wang, T., Yang, J., Zheng, S., Tong, J., Jiang, S., Zhang, X., & Zhang, K. (2023). Recent advances of targeting nicotinamide phosphoribosyltransferase (NAMPT) for cancer drug discovery. European journal of medicinal chemistry, 258, 115607.
[21] Gasparrini, M., & Audrito, V. (2022). NAMPT: A critical driver and therapeutic target for cancer. The international journal of biochemistry & cell biology, 145, 106189.
[22] Ammer, L. M., Vollmann-Zwerenz, A., Ruf, V., Wetzel, C. H., Riemenschneider, M. J., Albert, N. L., Beckhove, P., & Hau, P. (2020). The Role of Translocator Protein TSPO in Hallmarks of Glioblastoma. Cancers, 12(10), 2973.
[23] Bhoola, N. H., Mbita, Z., Hull, R., & Dlamini, Z. (2018). Translocator Protein (TSPO) as a Potential Biomarker in Human Cancers. International journal of molecular sciences, 19(8), 2176.
[24] Khwaza, V., Mlala, S., Oyedeji, O. O., & Aderibigbe, B. A. (2021). Pentacyclic Triterpenoids with Nitrogen-Containing Heterocyclic Moiety, Privileged Hybrids in Anticancer Drug Discovery. Molecules (Basel, Switzerland), 26(9), 2401.
[25] Ali, I., Lone, M. N., Al-Othman, Z. A., Al-Warthan, A., & Sanagi, M. M. (2015). Heterocyclic Scaffolds: Centrality in Anticancer Drug Development. Current drug targets, 16(7), 711–734.
[26] Ayana, R., Vijayakumar, B., Athulya, P., Anjana, V. S., Vismaya, K. V., & Swarnalatha, G. (2021). A short review on heterocyclic compounds showing Anti-Breast cancer activity. Journal of Scientific Research, 13(3), 1075–1098.
[27] Viegas-Junior, C., Danuello, A., da Silva Bolzani, V., Barreiro, E. J., & Fraga, C. A. (2007). Molecular hybridization: a useful tool in the design of new drug prototypes. Current medicinal chemistry, 14(17), 1829–1852. 
[28] Ganesh, B. H., Raj, A. G., Aruchamy, B., Nanjan, P., Drago, C., & Ramani, P. (2024). Pyrrole: A Decisive Scaffold for the Development of Therapeutic Agents and Structure-Activity Relationship. ChemMedChem, 19(1), e202300447.
[29] Pegklidou, K., Papastavrou, N., Gkizis, P., Komiotis, D., Balzarini, J., & Nicolaou, I. (2015). N-substituted pyrrole-based scaffolds as potential anticancer and antiviral lead structures. Medicinal chemistry (Shariqah (United Arab Emirates)), 11(6), 602–608.
[30] Mateev, E., Georgieva, M., & Zlatkov, A. (2022). Pyrrole as an Important Scaffold of Anticancer Drugs: Recent Advances. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for
 
Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 25, 24–40.
[31] Sahu, R., Shah, K., Gautam, Y., & Sahu, K. (2023). Pyrazine Moiety: Recent developments in cancer treatment. Current Organic Chemistry, 27(10), 821–843.
[32] Chen, G. Q., Guo, H. Y., Quan, Z. S., Shen, Q. K., Li, X., & Luan, T. (2023). Natural Products-Pyrazine Hybrids: A Review of Developments in Medicinal Chemistry. Molecules (Basel, Switzerland), 28(21), 7440.
[33] Jaballah, M. Y., Serya, R. T., & Abouzid, K. (2017). Pyridazine Based Scaffolds as Privileged Structures in anti-Cancer Therapy. Drug research, 67(3), 138–148.
[34] He, Z. X., Gong, Y. P., Zhang, X., Ma, L. Y., & Zhao, W. (2021). Pyridazine as a privileged structure: An updated review on anticancer activity of pyridazine containing bioactive molecules. European journal of medicinal chemistry, 209, 112946.
[35] Lish, A. B., Foroumadi, A., Kolvari, E., & Safari, F. (2023). Synthesis and Biological Evaluation of 12-Aryl-11-hydroxy-5,6-dihydropyrrolo[2″,1″:3′,4′]pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyridazine-8(9H)-one Derivatives as Potential Cytotoxic Agents. ACS Omega, 8(45), 42212–42224.[36] Liu, H., Li, Z., Huo, S., Wei, Q., & Ge, L. (2020). Induction of G0/G1 phase arrest and apoptosis by CRISPR/Cas9-mediated knockout of CDK2 in A375 melanocytes. Molecular and clinical oncology, 12(1), 9–14.
[37] Ayati, A., Oghabi Bakhshaiesh, T., Moghimi, S., Esmaeili, R., Majidzadeh-A, K., Safavi, M., Firoozpour, L., Emami, S., & Foroumadi, A. (2018). Synthesis and biological evaluation of new coumarins bearing 2,4-diaminothiazole-5-carbonyl moiety. European journal of medicinal chemistry, 155, 483–491.
Applied Chemistry Today
Volume 19, Issue 73
Autumn 2024
Pages 55-72